YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)


AddThis Social Bookmark Button

Avandia Bone Fracture &  Heart Attacks Attorneys

Avandia patients have been known to experience a higher-than-normal rate of bone fractures.  In December 2007, researchers doing experiments with mice discovered a possible reason for this Avandia side effect.   Avandia appears to throw the body’s system for removing and replacing old bone cells off balance in two important ways.   In addition to inhibiting the action of osteoblasts, cells in the body that build bone, researchers also discovered that Avandia  stimulates the action of osteoclasts, cells that degrade bone.  The Avandia researchers, whose work was published in the December 2007 issue of Nature Medicine, surmised that the medication’s effect on these cells could account for Avandia’s bone fracture side effects.  While there are medications available to counter the Avandia bone fracture risk, the authors of the December 2007 study recommended that all Avandia patients be monitored for bone problems.

About Avaindia and It's Side Effects
Avandia, manufactured by GlaxoSmithKline is a newer class of diabetes drugs called thiazolidinediones or glitazones, which increase the body's sensitivity to insulin. The FDA approved Avandia on May 25, 1999.

The American Heart Association and American Diabetes Association issued recommendations to guide the use of Avandia, a glucose-lowering drugs and other as thiazolidinediones (TZDs). Diabetics who have mild heart disease or any problems with their kidneys may be at an increased risk of developing congestive heart failure if they take certain diabetes medications, according to a new study.

The study, published in the September 9, 2003 issue of the Mayo Clinic Proceedings, reported on six cases of congestive heart failure in people taking Avandia to help control their diabetes. The researchers studied the records of six men, between the ages of 66 and 78 years, with Type-II diabetes who had gone to the emergency room at Dallas Veterans Affairs Medical Center emergency room.

All six patients complained of shortness of breath, swelling of their feet, and weight gain, which are symptoms of congestive heart failure and pulmonary edema (fluid buildup in the lungs). Congestive heart failure occurs when the heart can no longer pump enough blood to maintain adequate circulation. Because the heart doesn't pump properly, fluid often builds up in the lungs.

Four of the six people in this study had chronic renal insufficiency, which means that their kidneys weren't functioning normally. Only two had any previous signs of heart disease. Four of the six had high blood pressure. They had been on the diabetes medications for between one month and 16 months. Three people developed symptoms within one to three months after the dose of their diabetes drug had been increased.

The FDA and GlaxoSmithKline said on January 5, 2006 that patients who have taken Avandia reported blurry vision and swelling of the feet and legs. More than 6 million people worldwide have been prescribed Avandia.

GlaxoSmithKline stated they received very rare reports of new or worsening diabetic macular edema in diabetic patients who took Avandia. The swelling of the retina can cause blurry or distorted vision. Additionally, most of those patients also reported peripheral edema, or swelling of the legs, ankles and feet, according to a letter GlaxoSmithKline sent during December 2005 to doctors. In some situations, stopping treatment or reducing the dose eliminated or improved the condition, the letter added.

If you or a loved one took Avandia and suffered side effects including bone fractures and or a heart attacks, please fill out the form at the right for a free case evaluation by a Avanadia lawsuit lawyer.
AvandiaRSS Feed

FDA Planning Hiring Blitz

May 1, 2008 | Parker Waichman Alonso LLP
The beleaguered Food & Drug Administration (FDA) is planning on filling over 1,300 positions by the end of September, triple the amount hired by the FDA over the past two years.  The FDA will add 600 new jobs—including chemists, biologists, and statisticians—and will fill over 700 currently open posts.  Most of the new positions will be in the department charged with reviewing new drugs; 150 will be in field offices that inspect manufacturing plants and food...

Another Study Confirms Avandia, Actos Bone Fracture Risk

Apr 29, 2008 | Parker Waichman Alonso LLP
Avandia, a diabetes drug already mired in controversy, may double the risk of bone fractures, according to a new study.  The study, conducted by Swiss researchers, found a similar risk with the diabetes drug Actos.  Previous studies have found that these drugs increase the risk of bone fractures, but the Swiss study sheds light on how serious this problem might be.Avandia has been a subject of debate since last May, when an analysis of 42 clinical trails published by the Cleveland...

FDA Considering Biomarkers As a Way to Improve Drug Safety

Apr 17, 2008 | Parker Waichman Alonso LLP
A new way of testing experimental drugs is being considered by the Food & Drug Administration (FDA).  If adopted, the FDA could end up requiring "biomarker" tests for all new drugs.  Proponents of the new biomarker process say it would help bring new drugs to market more quickly, while at the same time, reduce the risk that patients might be exposed to dangerous side effects that aren't apparent when new drugs are tested in animals.  However, some patient advocates,...

FDA Reprimands Glaxo for Avandia Study

Apr 8, 2008 | Parker Waichman Alonso LLP
The US Food and Drug Administration Federal (FDA) has just issued a warning to the drug maker, GlaxoSmithKline, for not reporting safety results on its diabetes pill Avandia.  Avandia received the prominent, “Black Box” warning label last year and the FDA said that between 2001 and 2007 GlaxoSmithKline neglected to update the agency on over 10 ongoing studies of Avandia, as required by regulations.  The FDA acknowledges that information from those studies were included and...

More Heat for Vytorin and Avandia

Mar 5, 2008 | Parker Waichman Alonso LLP
Avandia and Vytorin are the subject of yet another government investigation.  The Government Accountability Office (GAO) will look into whether the US Food and Drug Administration’s (FDA) drug-review process cleared two popular medications without sufficient proof of their safety or effectiveness.  Senator Charles E. Grassley (Republican-Iowa) requested the GAO investigation after recent studies suggested that the diabetes pill Avandia increases the risk of cardiac problems in...

More Avandia News

Avandia
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News